相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Modification of Crocodile Spermatozoa Refutes the Tenet That Post-testicular Sperm Maturation Is Restricted To Mammals
Brett Nixon et al.
MOLECULAR & CELLULAR PROTEOMICS (2019)
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
S. Degryse et al.
LEUKEMIA (2018)
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia
Maro Ohanian et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Insight into the inhibitor discrimination by FLT3F691L
Sharad Verma et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2018)
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
Jorge Cortes et al.
LANCET ONCOLOGY (2018)
Somatic mutations precede myeloid leukemia years before diagnosis
Pinkal Desai et al.
NATURE MEDICINE (2018)
Determinants and clinical implications of chromosomal instability in cancer
Laurent Sansregret et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Prediction of acute myeloid leukaemia risk in healthy individuals
Sagi Abelson et al.
NATURE (2018)
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor
Lauren Y. Lee et al.
BLOOD (2017)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer
Heather C. Murray et al.
EXPERT OPINION ON DRUG DISCOVERY (2017)
FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia
Ines Peschel et al.
HAEMATOLOGICA (2017)
Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment
Gabriel Ghiaur et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2017)
Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia
Hubert Hackl et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
Alexander E. Perl et al.
LANCET ONCOLOGY (2017)
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
R. Hehlmann et al.
LEUKEMIA (2017)
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
Maria Larrosa-Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Tracing the origins of relapse in acute myeloid leukaemia to stem cells
Liran I. Shlush et al.
NATURE (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The target landscape of clinical kinase drugs
Susan Klaeger et al.
SCIENCE (2017)
Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199
Kiran Naqvi et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors
Bao Nguyen et al.
ONCOTARGET (2017)
FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia
Ines Peschel et al.
HAEMATOLOGICA (2017)
Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
Federico Mosna et al.
JOURNAL OF CLINICAL MEDICINE (2017)
Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia
M. Ryan Corces et al.
FRONTIERS IN ONCOLOGY (2017)
Sorafenib plus 5-azacytidine (AZA) in older untreated FLT3-ITD mutated AML.
Maro Ohanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
CD34+CD38-CD123+Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection
Adhra Al-Mawali et al.
ACTA HAEMATOLOGICA (2017)
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
Andrew H. Wei et al.
BLOOD (2017)
KinMap: a web-based tool for interactive navigation through human kinome data
Sameh Eid et al.
BMC BIOINFORMATICS (2017)
The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells
E. Chang et al.
LEUKEMIA (2016)
Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD
Anthony D. Ho et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Elie Traer et al.
CANCER RESEARCH (2016)
Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+delineate FLT3/ITD-positive clones
Adhra Al-Mawali et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
A 17-gene stemness score for rapid determination of risk in acute leukaemia
Stanley W. K. Ng et al.
NATURE (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia
Sara E. Meyer et al.
CANCER DISCOVERY (2016)
Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing
Bianhong Wang et al.
ONCOTARGET (2016)
Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model
Jennifer L. Poitras et al.
ONCOTARGET (2016)
A phase 3, open-label, randomized study of the FLT3 inhibitor gilteritinib versus salvage chemotherapy in adults with first relapse or primary refractory FLT3 mutation-positive acute myeloid leukemia.
Alexander E. Perl et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse
Manoj Garg et al.
BLOOD (2015)
Proteogenomics: emergence and promise
Sam Faulkner et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2015)
A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia
Daniela F. Angelini et al.
CLINICAL CANCER RESEARCH (2015)
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Christoph Rollig et al.
LANCET ONCOLOGY (2015)
Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia
I-K Park et al.
LEUKEMIA (2015)
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
C. C. Smith et al.
LEUKEMIA (2015)
Targeting novel signaling pathways for resistant acute myeloid leukemia
Kathleen M. Sakamoto et al.
MOLECULAR GENETICS AND METABOLISM (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting FLT3 to treat leukemia
Heiko Konig et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Allison Galanis et al.
BLOOD (2014)
Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase
Xiaochuan Yang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Treatment With FLT3 Inhibitor in Patients With FLT3-Mutated Acute Myeloid Leukemia Is Associated With Development of Secondary FLT3-Tyrosine Kinase Domain Mutations
Yesid Alvarado et al.
CANCER (2014)
SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
Alexandre Puissant et al.
CANCER CELL (2014)
Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
Sanam Loghavi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia
F. Ravandi et al.
LEUKEMIA (2014)
Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis
M. R. Corces-Zimmerman et al.
LEUKEMIA (2014)
Age-related mutations associated with clonal hematopoietic expansion and malignancies
Mingchao Xie et al.
NATURE MEDICINE (2014)
Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia
Hanna Janke et al.
PLOS ONE (2014)
Overview of Therapy and Strategies for Optimizing Outcomes in De Novo Pediatric Acute Myeloid Leukemia
Kelly Faulk et al.
PEDIATRIC DRUGS (2014)
Overcoming Myelosuppression Due to Synthetic Lethal Toxicity in FLT3-Targeted Acute Myeloid Leukemia Therapy
Alexander A. Warkentin et al.
ELIFE (2014)
Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia
Brian Parkin et al.
BLOOD (2013)
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Farhad Ravandi et al.
BLOOD (2013)
Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD-Positive Acute Myeloid Leukemia
Sharyn D. Baker et al.
CLINICAL CANCER RESEARCH (2013)
Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
Kerstin Maria Kampa-Schittenhelm et al.
MOLECULAR CANCER (2013)
Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia
S. Wakita et al.
LEUKEMIA (2013)
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors
A. B. Williams et al.
LEUKEMIA (2013)
Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009
Yiming Chen et al.
LEUKEMIA & LYMPHOMA (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice
Emily Bailey et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
Mark Levis
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias
Nicholas A. Zorko et al.
BLOOD (2012)
Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model
Sarah Greenblatt et al.
BLOOD (2012)
The Origin and Evolution of Mutations in Acute Myeloid Leukemia
John S. Welch et al.
CELL (2012)
FLT3-ITD Knockin Impairs Hematopoietic Stem Cell Quiescence/Homeostasis, Leading to Myeloproliferative Neoplasm
S. Haihua Chu et al.
CELL STEM CELL (2012)
Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia
Jana Markova et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Boulevard of Broken Dreams: Drug Approval for Older Adults With Acute Myeloid Leukemia
Mikkael A. Sekeres et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
A. S. Moore et al.
LEUKEMIA (2012)
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors
E. Weisberg et al.
LEUKEMIA (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
Clonal Architecture of Secondary Acute Myeloid Leukemia
Matthew J. Walter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment
Tiziana Grafone et al.
ONCOLOGY REVIEWS (2012)
Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases
Kenneth Verstraete et al.
NATURE REVIEWS CANCER (2012)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis et al.
BLOOD (2011)
Prognostic Value of FLT3 Mutations Among Different Cytogenetic Subgroups in Acute Myeloid Leukemia
Fabio P. S. Santos et al.
CANCER (2011)
Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia
Hiroto Inaba et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
FLT3 internal tandem duplication associates with adverse outcome and gene-and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Susan P. Whitman et al.
BLOOD (2010)
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
David Grimwade et al.
BLOOD (2010)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Robust Error Model for iTRAQ Quantification Reveals Divergent Signaling between Oncogenic FLT3 Mutants in Acute Myeloid Leukemia
Yi Zhang et al.
MOLECULAR & CELLULAR PROTEOMICS (2010)
Accumulation of driver and passenger mutations during tumor progression
Ivana Bozic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML
Frank Breitenbuecher et al.
BLOOD (2009)
Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality
Dirk Schmidt-Arras et al.
BLOOD (2009)
FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
Nikolas von Bubnoff et al.
CANCER RESEARCH (2009)
Mechanisms of resistance to FLT3 inhibitors
S. Haihua Chu et al.
DRUG RESISTANCE UPDATES (2009)
Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation
Elena Razumovskaya et al.
EXPERIMENTAL HEMATOLOGY (2009)
Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes
Chunaram Choudhary et al.
MOLECULAR CELL (2009)
Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease
Adam J. Mead et al.
BLOOD (2008)
Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model
Li Li et al.
BLOOD (2008)
Mutant FLT3:: A direct target of sorafenib in acute myelogenous leukemia
Weiguo Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype
Krzysztof Mrozek
SEMINARS IN ONCOLOGY (2008)
Prognostic relevance of FLT3-TKD mutations in AML:: the combination matters -: an analysis of 3082 patients
Ulrike Bacher et al.
BLOOD (2008)
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications
Susan P. Whitman et al.
BLOOD (2008)
Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin
Elly V. Barry et al.
BLOOD (2007)
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
Stefan Froehling et al.
CANCER CELL (2007)
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations
Rama Krishna Kancha et al.
EXPERIMENTAL HEMATOLOGY (2007)
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia
Adam J. Mead et al.
BLOOD (2007)
Aberrant marker expression patterns on the CD34+CD38-stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission
A. van Rhenen et al.
LEUKEMIA (2007)
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
Jan J. Cornelissen et al.
BLOOD (2007)
Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD
M. Okamoto et al.
LEUKEMIA (2007)
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways
Obdulio Piloto et al.
BLOOD (2007)
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
Daniel J. DeAngelo et al.
BLOOD (2006)
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
Steven Knapper et al.
BLOOD (2006)
Constitutively activated FLT3 phosphorylates BAD partially through Pim-1
Kyu-Tae Kim et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2
Elke Heiss et al.
BLOOD (2006)
Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML
C Reindl et al.
BLOOD (2006)
Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations
HS Radomska et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
F Heidel et al.
BLOOD (2006)
Genetics of myeloid malignancies:: Pathogenetic and clinical implications
S Fröhling et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis
M Yanada et al.
LEUKEMIA (2005)
AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations
C Choudhary et al.
BLOOD (2005)
FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model
R Grundler et al.
BLOOD (2005)
FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)
K Bagrintseva et al.
BLOOD (2005)
Prognostic index for adult patients with acute myeloid leukemia in first relapse
DA Breems et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
FLT3/ITD mutation signaling includes suppression of SHP-1
PL Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival
KT Kim et al.
BLOOD (2005)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)
T Kindler et al.
BLOOD (2005)
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
W Fiedler et al.
BLOOD (2005)
Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells
K Bagrintseva et al.
BLOOD (2004)
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22):: Results from CALGB 8461
JC Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The structural basis for autoinhibition of FLT3 by the juxtamembrane domain
J Griffith et al.
MOLECULAR CELL (2004)
Concepts of human leukemic development
JK Warner et al.
ONCOGENE (2004)
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML
JR Jiang et al.
BLOOD (2004)
Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia
J Cools et al.
CANCER RESEARCH (2004)
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells
KWH Yee et al.
BLOOD (2004)
Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity
KJ Hope et al.
NATURE IMMUNOLOGY (2004)
Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518
JJ Clark et al.
BLOOD (2004)
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
BD Smith et al.
BLOOD (2004)
The role of FLT3 in haematopoietic malignancies
DL Stirewalt et al.
NATURE REVIEWS CANCER (2003)
Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor
R Grundler et al.
BLOOD (2003)
Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations
M Mizuki et al.
BLOOD (2003)
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461)
JC Byrd et al.
BLOOD (2002)
A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia
K Spiekermann et al.
BLOOD (2002)
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia:: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
S Schnittger et al.
BLOOD (2002)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model
LM Kelly et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
E Weisberg et al.
CANCER CELL (2002)
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
M Levis et al.
BLOOD (2002)
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
LM Kelly et al.
CANCER CELL (2002)
Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain
H Kiyoi et al.
ONCOGENE (2002)
FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
LM Kelly et al.
BLOOD (2002)
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia
FM Abu-Duhier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
Molecular genetics of acute myeloid leukaemia
A Dash et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2001)
Flt3 ligand induces tyrosine phosphorylation of Gab1 and Gab2 and their association with Shp-2, grb2, and P13 kinase
SL Zhang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling
SL Zhang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
